EU MDR Clinical Evidence: Mastering CERs, PMCF, and Equivalence Arguments

This episode delves into the stringent clinical evidence requirements under the European Union's Medical Device Regulation (MDR 2017/745). We explore the top challenges manufacturers face, including the heightened standards for clinical evaluation plans and reports (CEPs/CERs), the complexities of justifying 'sufficient data,' the difficulties in making equivalence arguments, and the continuous nature of Post-Market Clinical Follow-up (PMCF). Key Questions - What does "sufficient clinical evidence" truly mean under the EU MDR? - Why are so many companies forced to rewrite their Clinical Evaluation Reports (CERs)? - How have the rules for claiming equivalence to another device changed? - Is Post-Market Clinical Follow-up (PMCF) optional or a continuous requirement? - How do you align your marketing claims, risk management, and PMS data? - What are the biggest clinical data hurdles for borderline and Class IIa/IIb devices? - How can you prepare your clinical evaluation for stricter Notified Body scrutiny? Pure Global streamlines global market access for MedTech and IVD companies navigating complex regulations like the EU MDR. Our experts develop robust regulatory strategies and use advanced AI to efficiently compile technical dossiers and Clinical Evaluation Reports, ensuring alignment with Notified Body expectations. We manage the entire lifecycle, from pre-submission to Post-Market Clinical Follow-up and surveillance, acting as your local representative in over 30 markets. Let us help you meet the high standards for clinical evidence and accelerate your entry into the EU and beyond. Contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.